Dismay as Alzheimer's drug fails in clinical trials
by Hannah Devlin Science correspondent from on (#22PKG)
Final-stage results dash hopes that solanezumab, an injectable antibody, would provide treatment breakthrough
A drug that was seen as a strong contender to slow the progression of Alzheimer's disease has failed to deliver in the final stage of clinical trials.
The results, based on 2,000 patients with mild dementia, are a significant blow because there are currently no treatments to slow the effects of Alzheimer's. Few have made it to phase 3 trials.
Continue reading...